Entropy Technologies LP Sells 7,114 Shares of Doximity, Inc. (NASDAQ:DOCS)

Entropy Technologies LP lessened its holdings in shares of Doximity, Inc. (NASDAQ:DOCSFree Report) by 54.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,835 shares of the company’s stock after selling 7,114 shares during the quarter. Entropy Technologies LP’s holdings in Doximity were worth $254,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Fountainhead AM LLC purchased a new position in shares of Doximity in the third quarter worth $710,000. Blair William & Co. IL grew its position in shares of Doximity by 31.7% during the first quarter. Blair William & Co. IL now owns 90,600 shares of the company’s stock valued at $2,438,000 after purchasing an additional 21,787 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Doximity by 1,824.5% in the second quarter. Federated Hermes Inc. now owns 279,634 shares of the company’s stock worth $7,821,000 after purchasing an additional 265,104 shares during the last quarter. AXA S.A. lifted its position in shares of Doximity by 40.2% in the second quarter. AXA S.A. now owns 216,392 shares of the company’s stock worth $6,052,000 after buying an additional 61,992 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Doximity by 128.7% during the first quarter. Acadian Asset Management LLC now owns 96,442 shares of the company’s stock valued at $2,590,000 after buying an additional 54,281 shares during the last quarter. 87.19% of the stock is owned by hedge funds and other institutional investors.

Doximity Price Performance

DOCS stock opened at $49.40 on Friday. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $61.75. The firm’s 50-day moving average is $43.40 and its 200 day moving average is $34.18. The company has a market capitalization of $9.17 billion, a PE ratio of 56.78, a P/E/G ratio of 4.51 and a beta of 1.30.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DOCS. Raymond James reaffirmed an “outperform” rating and set a $65.00 price objective (up from $37.00) on shares of Doximity in a report on Friday, November 8th. The Goldman Sachs Group initiated coverage on shares of Doximity in a research report on Friday. They set a “neutral” rating and a $58.00 price objective for the company. Evercore ISI upped their target price on shares of Doximity from $34.00 to $45.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. KeyCorp upgraded Doximity from a “sector weight” rating to an “overweight” rating and set a $70.00 price target for the company in a research report on Friday, November 8th. Finally, Baird R W upgraded Doximity to a “strong-buy” rating in a research report on Tuesday, September 17th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Doximity currently has a consensus rating of “Hold” and a consensus price target of $51.07.

Get Our Latest Stock Report on Doximity

Doximity Company Profile

(Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Further Reading

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NASDAQ:DOCSFree Report).

Institutional Ownership by Quarter for Doximity (NASDAQ:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.